Antiviral treatment fails to slow early-stage Alzheimer’s

July 29, 2025

The idea that herpes infections trigger or contribute to Alzheimer’s disease has been gaining favor among some scientists, raising hope that herpes treatments could slow the progression of Alzheimer’s symptoms among patients.

AAAAI: Omalizumab as effective as multifood oral immunotherapy for individuals with food allergy
Individuals with one to three allergenic foods are able to introduce and continue eating allergenic foods at 12 months after multifood oral immunotherapy (mOIT) or omalizumab, according to a study presented at the annual meeting of the American Academy of Allergy, Asthma & Immunology, held from Feb. 27 to March 2 in Philadelphia.
Feeling stressed? These immune cells might be key to understanding why
There are many ways that the human body responds to stress, from the adrenaline rush of the "fight-or-flight" instinct to more subtle, complex changes that may not be immediately recognizable to us.
AAOS: GLP-1 receptor agonist use increases five-year risk for osteoporosis
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes and obesity is independently associated with a significantly increased five-year risk for osteoporosis, gout, and osteomalacia compared with nonuse, according to a study presented at the annual meeting of the American Academy of Orthopaedic Surgeons, held from March 2 to 6 in New Orleans.
Greater quality of life, higher satisfaction seen with robotic-assisted total knee arthroplasty
Robotic-assisted total knee arthroplasty (raTKA) is associated with higher satisfaction and greater improvement in quality of life (QOL) than conventional TKA (cTKA), according to a study presented at the annual meeting of the American Academy of Orthopedic Surgeons, held from March 2 to 6 in New Orleans.
Blood-based marker opens up perspectives for cancer diagnostics
Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation therapy. Reliable markers that can be used to predict aggressive tumor progression and treatment success at an early stage are still largely lacking.

Antiviral treatment fails to slow early-stage Alzheimer’s

Recent Posts

JUST IN